Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. Baselin...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2023-03, Vol.181, p.42-52 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52 |
|---|---|
| container_issue | |
| container_start_page | 42 |
| container_title | European journal of cancer (1990) |
| container_volume | 181 |
| creator | Sabatier, Renaud Rousseau, Frédérique Joly, Florence Cropet, Claire Montégut, Coline Frindte, Johanna Cinieri, Saverio Guerra Alía, Eva M. Polterauer, Stephan Yoshida, Hiroyuki Vergote, Ignace Colombo, Nicoletta Hietanen, Sakari Largillier, Rémi Canzler, Ulrich Gratet, Alain Marmé, Frederik Favier, Laure Pujade-Lauraine, Eric Ray-Coquard, Isabelle |
| description | The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1.
Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients ( |
| doi_str_mv | 10.1016/j.ejca.2022.11.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2765773993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804922017798</els_id><sourcerecordid>2795544718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-1613a30670341f584bf1e35e88d07896c249324260d6819722af50d5ced90c783</originalsourceid><addsrcrecordid>eNp9kUtuFDEQhlsIRIbABVggS2zYdMfvtiU2o2gISCOGRVhbbncZPOrHYHePNNwgB-FiOUncTGDBglUt6qtfVfUVxWuCK4KJvNpXsHe2opjSipAKU_2kWBFV6xIrQZ8WK6yFLhXm-qJ4kdIeY1wrjp8XF0xKxpnSq-Ju431w1p2QHVqUrIfphEaPehuGCQY7OEBjZw82huY30sDRuvBz7m2DwoDGY-7YAbmFjOhgpwDDlJD9Bi26v_slBTqBjQn5OPZo-g7oy3q3XZfkavP5Zndbjkcq0JQjupfFM2-7BK8e62Xx9cPm9vpjud3dfLpeb0vHqZpKIgmzDMsaM068ULzxBJgApdp8nZaOcs0opxK3UhFdU2q9wK1w0GrsasUui3fn3EMcf8yQJtOH5KDr7ADjnAytpahrpjXL6Nt_0P04xyFvlyktBOc1WQLpmXJxTCmCN4cYehtPhmCziDJ7s4gyiyhDiMmi8tCbx-i56aH9O_LHTAbenwHIvzgGiCa5_Np8RojgJtOO4X_5D0EPomQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2795544718</pqid></control><display><type>article</type><title>Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sabatier, Renaud ; Rousseau, Frédérique ; Joly, Florence ; Cropet, Claire ; Montégut, Coline ; Frindte, Johanna ; Cinieri, Saverio ; Guerra Alía, Eva M. ; Polterauer, Stephan ; Yoshida, Hiroyuki ; Vergote, Ignace ; Colombo, Nicoletta ; Hietanen, Sakari ; Largillier, Rémi ; Canzler, Ulrich ; Gratet, Alain ; Marmé, Frederik ; Favier, Laure ; Pujade-Lauraine, Eric ; Ray-Coquard, Isabelle</creator><creatorcontrib>Sabatier, Renaud ; Rousseau, Frédérique ; Joly, Florence ; Cropet, Claire ; Montégut, Coline ; Frindte, Johanna ; Cinieri, Saverio ; Guerra Alía, Eva M. ; Polterauer, Stephan ; Yoshida, Hiroyuki ; Vergote, Ignace ; Colombo, Nicoletta ; Hietanen, Sakari ; Largillier, Rémi ; Canzler, Ulrich ; Gratet, Alain ; Marmé, Frederik ; Favier, Laure ; Pujade-Lauraine, Eric ; Ray-Coquard, Isabelle</creatorcontrib><description>The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1.
Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed.
Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41–0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49–0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib.
Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.
•Older patients in PAOLA-1 had unfavourable baseline clinical and molecular features.•Benefits of olaparib plus bevacizumab were similar in older and younger patients.•Improved progression-free survival was limited to those with HRD-positive tumours.•Safety and tolerability profiles were similar in older and younger patients.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2022.11.029</identifier><identifier>PMID: 36634389</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Anemia ; Bevacizumab ; Bevacizumab - adverse effects ; BRCA1 protein ; Breast cancer ; Cancer ; Effectiveness ; Elderly ; Female ; Homologous recombination ; Homology ; Humans ; Hypertension ; Maintenance ; Monoclonal antibodies ; Mutation ; Neoplasm Recurrence, Local - drug therapy ; Olaparib ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - pathology ; Patients ; Phthalazines - adverse effects ; Piperazines - adverse effects ; Safety ; Subgroups ; Survival ; Targeted cancer therapy ; Tumors</subject><ispartof>European journal of cancer (1990), 2023-03, Vol.181, p.42-52</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Mar 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-1613a30670341f584bf1e35e88d07896c249324260d6819722af50d5ced90c783</citedby><cites>FETCH-LOGICAL-c428t-1613a30670341f584bf1e35e88d07896c249324260d6819722af50d5ced90c783</cites><orcidid>0000-0002-0618-3800 ; 0000-0003-4734-4743 ; 0000-0002-7589-8981 ; 0000-0002-5821-682X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804922017798$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36634389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sabatier, Renaud</creatorcontrib><creatorcontrib>Rousseau, Frédérique</creatorcontrib><creatorcontrib>Joly, Florence</creatorcontrib><creatorcontrib>Cropet, Claire</creatorcontrib><creatorcontrib>Montégut, Coline</creatorcontrib><creatorcontrib>Frindte, Johanna</creatorcontrib><creatorcontrib>Cinieri, Saverio</creatorcontrib><creatorcontrib>Guerra Alía, Eva M.</creatorcontrib><creatorcontrib>Polterauer, Stephan</creatorcontrib><creatorcontrib>Yoshida, Hiroyuki</creatorcontrib><creatorcontrib>Vergote, Ignace</creatorcontrib><creatorcontrib>Colombo, Nicoletta</creatorcontrib><creatorcontrib>Hietanen, Sakari</creatorcontrib><creatorcontrib>Largillier, Rémi</creatorcontrib><creatorcontrib>Canzler, Ulrich</creatorcontrib><creatorcontrib>Gratet, Alain</creatorcontrib><creatorcontrib>Marmé, Frederik</creatorcontrib><creatorcontrib>Favier, Laure</creatorcontrib><creatorcontrib>Pujade-Lauraine, Eric</creatorcontrib><creatorcontrib>Ray-Coquard, Isabelle</creatorcontrib><title>Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1.
Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed.
Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41–0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49–0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib.
Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.
•Older patients in PAOLA-1 had unfavourable baseline clinical and molecular features.•Benefits of olaparib plus bevacizumab were similar in older and younger patients.•Improved progression-free survival was limited to those with HRD-positive tumours.•Safety and tolerability profiles were similar in older and younger patients.</description><subject>Aged</subject><subject>Anemia</subject><subject>Bevacizumab</subject><subject>Bevacizumab - adverse effects</subject><subject>BRCA1 protein</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Effectiveness</subject><subject>Elderly</subject><subject>Female</subject><subject>Homologous recombination</subject><subject>Homology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Maintenance</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Olaparib</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Patients</subject><subject>Phthalazines - adverse effects</subject><subject>Piperazines - adverse effects</subject><subject>Safety</subject><subject>Subgroups</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtuFDEQhlsIRIbABVggS2zYdMfvtiU2o2gISCOGRVhbbncZPOrHYHePNNwgB-FiOUncTGDBglUt6qtfVfUVxWuCK4KJvNpXsHe2opjSipAKU_2kWBFV6xIrQZ8WK6yFLhXm-qJ4kdIeY1wrjp8XF0xKxpnSq-Ju431w1p2QHVqUrIfphEaPehuGCQY7OEBjZw82huY30sDRuvBz7m2DwoDGY-7YAbmFjOhgpwDDlJD9Bi26v_slBTqBjQn5OPZo-g7oy3q3XZfkavP5Zndbjkcq0JQjupfFM2-7BK8e62Xx9cPm9vpjud3dfLpeb0vHqZpKIgmzDMsaM068ULzxBJgApdp8nZaOcs0opxK3UhFdU2q9wK1w0GrsasUui3fn3EMcf8yQJtOH5KDr7ADjnAytpahrpjXL6Nt_0P04xyFvlyktBOc1WQLpmXJxTCmCN4cYehtPhmCziDJ7s4gyiyhDiMmi8tCbx-i56aH9O_LHTAbenwHIvzgGiCa5_Np8RojgJtOO4X_5D0EPomQ</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Sabatier, Renaud</creator><creator>Rousseau, Frédérique</creator><creator>Joly, Florence</creator><creator>Cropet, Claire</creator><creator>Montégut, Coline</creator><creator>Frindte, Johanna</creator><creator>Cinieri, Saverio</creator><creator>Guerra Alía, Eva M.</creator><creator>Polterauer, Stephan</creator><creator>Yoshida, Hiroyuki</creator><creator>Vergote, Ignace</creator><creator>Colombo, Nicoletta</creator><creator>Hietanen, Sakari</creator><creator>Largillier, Rémi</creator><creator>Canzler, Ulrich</creator><creator>Gratet, Alain</creator><creator>Marmé, Frederik</creator><creator>Favier, Laure</creator><creator>Pujade-Lauraine, Eric</creator><creator>Ray-Coquard, Isabelle</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0618-3800</orcidid><orcidid>https://orcid.org/0000-0003-4734-4743</orcidid><orcidid>https://orcid.org/0000-0002-7589-8981</orcidid><orcidid>https://orcid.org/0000-0002-5821-682X</orcidid></search><sort><creationdate>202303</creationdate><title>Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial</title><author>Sabatier, Renaud ; Rousseau, Frédérique ; Joly, Florence ; Cropet, Claire ; Montégut, Coline ; Frindte, Johanna ; Cinieri, Saverio ; Guerra Alía, Eva M. ; Polterauer, Stephan ; Yoshida, Hiroyuki ; Vergote, Ignace ; Colombo, Nicoletta ; Hietanen, Sakari ; Largillier, Rémi ; Canzler, Ulrich ; Gratet, Alain ; Marmé, Frederik ; Favier, Laure ; Pujade-Lauraine, Eric ; Ray-Coquard, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-1613a30670341f584bf1e35e88d07896c249324260d6819722af50d5ced90c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Anemia</topic><topic>Bevacizumab</topic><topic>Bevacizumab - adverse effects</topic><topic>BRCA1 protein</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Effectiveness</topic><topic>Elderly</topic><topic>Female</topic><topic>Homologous recombination</topic><topic>Homology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Maintenance</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Olaparib</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Patients</topic><topic>Phthalazines - adverse effects</topic><topic>Piperazines - adverse effects</topic><topic>Safety</topic><topic>Subgroups</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sabatier, Renaud</creatorcontrib><creatorcontrib>Rousseau, Frédérique</creatorcontrib><creatorcontrib>Joly, Florence</creatorcontrib><creatorcontrib>Cropet, Claire</creatorcontrib><creatorcontrib>Montégut, Coline</creatorcontrib><creatorcontrib>Frindte, Johanna</creatorcontrib><creatorcontrib>Cinieri, Saverio</creatorcontrib><creatorcontrib>Guerra Alía, Eva M.</creatorcontrib><creatorcontrib>Polterauer, Stephan</creatorcontrib><creatorcontrib>Yoshida, Hiroyuki</creatorcontrib><creatorcontrib>Vergote, Ignace</creatorcontrib><creatorcontrib>Colombo, Nicoletta</creatorcontrib><creatorcontrib>Hietanen, Sakari</creatorcontrib><creatorcontrib>Largillier, Rémi</creatorcontrib><creatorcontrib>Canzler, Ulrich</creatorcontrib><creatorcontrib>Gratet, Alain</creatorcontrib><creatorcontrib>Marmé, Frederik</creatorcontrib><creatorcontrib>Favier, Laure</creatorcontrib><creatorcontrib>Pujade-Lauraine, Eric</creatorcontrib><creatorcontrib>Ray-Coquard, Isabelle</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sabatier, Renaud</au><au>Rousseau, Frédérique</au><au>Joly, Florence</au><au>Cropet, Claire</au><au>Montégut, Coline</au><au>Frindte, Johanna</au><au>Cinieri, Saverio</au><au>Guerra Alía, Eva M.</au><au>Polterauer, Stephan</au><au>Yoshida, Hiroyuki</au><au>Vergote, Ignace</au><au>Colombo, Nicoletta</au><au>Hietanen, Sakari</au><au>Largillier, Rémi</au><au>Canzler, Ulrich</au><au>Gratet, Alain</au><au>Marmé, Frederik</au><au>Favier, Laure</au><au>Pujade-Lauraine, Eric</au><au>Ray-Coquard, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2023-03</date><risdate>2023</risdate><volume>181</volume><spage>42</spage><epage>52</epage><pages>42-52</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1.
Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed.
Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41–0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49–0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib.
Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.
•Older patients in PAOLA-1 had unfavourable baseline clinical and molecular features.•Benefits of olaparib plus bevacizumab were similar in older and younger patients.•Improved progression-free survival was limited to those with HRD-positive tumours.•Safety and tolerability profiles were similar in older and younger patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36634389</pmid><doi>10.1016/j.ejca.2022.11.029</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0618-3800</orcidid><orcidid>https://orcid.org/0000-0003-4734-4743</orcidid><orcidid>https://orcid.org/0000-0002-7589-8981</orcidid><orcidid>https://orcid.org/0000-0002-5821-682X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2023-03, Vol.181, p.42-52 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2765773993 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Anemia Bevacizumab Bevacizumab - adverse effects BRCA1 protein Breast cancer Cancer Effectiveness Elderly Female Homologous recombination Homology Humans Hypertension Maintenance Monoclonal antibodies Mutation Neoplasm Recurrence, Local - drug therapy Olaparib Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Patients Phthalazines - adverse effects Piperazines - adverse effects Safety Subgroups Survival Targeted cancer therapy Tumors |
| title | Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T15%3A15%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20maintenance%20olaparib%20and%20bevacizumab%20in%20ovarian%20cancer%20patients%20aged%20%E2%89%A565%20years%20from%20the%20PAOLA-1/ENGOT-ov25%20trial&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Sabatier,%20Renaud&rft.date=2023-03&rft.volume=181&rft.spage=42&rft.epage=52&rft.pages=42-52&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2022.11.029&rft_dat=%3Cproquest_cross%3E2795544718%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2795544718&rft_id=info:pmid/36634389&rft_els_id=S0959804922017798&rfr_iscdi=true |